Akorn, Inc. (AKRX) Beats Q4 Expectations

Akorn, Inc. (AKRX) reported fourth quarter EPS of $0.50 before the opening bell Thursday, compared to the consensus estimate of $0.45. Revenues increased 168% from last year to $227.8 million. Analysts expected revenues of $218.9 million. The stock is now up $2.29, or 4.50%, to $48.69.

For full year 2014, the company said consolidated revenue was $601.9 million and included $52.2 million of costs associated with competitive pricing actions during the second half of the year. GAAP EPS was $0.38 vs. adjusted non-GAAP EPS of $1.16.

For FY’15, AKRX provided EPS guidance of $1.88-$1.98 versus consensus of $1.82 per share. The company also issued revenue projection of $960-$980 million, compared to the consensus revenue estimate of $909.07 million.

On valuation measures, Akorn Inc. shares, which currently have an average 3-month trading volume of 1.3 million shares, trade at a trailing-12 P/E of 239.18, a forward P/E of 25.49 and a P/E to growth ratio of 1.22. The median Wall Street price target on the name is $49.50 with a high target of $55.00. Currently ticker boasts 11 ‘Buy’ endorsements, compared to 3 ’Holds’ and no ‘Sell’.

Profitability-wise, AKRX has a t-12 profit and operating margin of 5.09% and 21.55%, respectively. The $5.00 billion market cap company reported $70.07 million in cash vs. $1.16 billion in debt in its most recent quarter.

AKRX currently prints a one year return of about 72% and a year-to-date return of 28.18%.

Akorn Inc. is a manufacturer of diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the U.S. and internationally. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.

Be the first to comment

Leave a Reply

Your email address will not be published.


*